{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:59:54Z","timestamp":1781711994992,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Acylcarnitines play a crucial role in energy metabolism pathways, primarily known for their involvement in the beta oxidation of fatty acids. However, their roles extend beyond mitochondrial transport; they also contribute to the synthesis of lipids in the brain. The alteration of both plasma and cerebrospinal fluid (CSF) acylcarnitine levels has been reported in various central nervous system (CNS) disorders. However, existing CSF acylcarnitine analysis has primarily focused on adults, highlighting a critical gap in paediatrics, and plasma may not fully reflect CNS-specific metabolic changes. This study aimed to establish reference ranges of CSF acylcarnitine concentrations in paediatric patients. Using LC-MS\/MS, we profiled CSF acylcarnitines in 57 non-meningitis children. The acylcarnitine concentrations reported in this study range from 0.01 \u00b5M to 4.21 \u00b5M. These findings provide a critical reference for future research exploring the role of acylcarnitines in paediatric CNS disorders, bridging a significant gap in the current understanding of acylcarnitine metabolism in children.<\/jats:p>","DOI":"10.3389\/fmolb.2025.1643667","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:16:50Z","timestamp":1759292210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Paediatric CSF acylcarnitine reference ranges"],"prefix":"10.3389","volume":"12","author":[{"given":"Ontefetse Neo","family":"Plaatjie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marceline","family":"Tutu Van Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan","family":"Solomons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Van Der Kuip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayne","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"B1","volume-title":"Targeted metabolomics analysis of cerebrospinal fluid using the AbsoluteIDQ\u2122 kit (application note 1003-1)","author":"Bogumil","year":"2008"},{"key":"B2","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.26992","article-title":"Metabolic profiling of Parkinson's disease and mild cognitive impairment","volume":"32","author":"Burt\u00e9","year":"2017","journal-title":"Mov. Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11306-020-1648-5","article-title":"Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry","volume":"16","author":"Carlsson","year":"2020","journal-title":"Metabolomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0155694","DOI":"10.1371\/journal.pone.0155694","article-title":"Serum levels of acyl-carnitines along the continuum from normal to Alzheimer's dementia","volume":"11","author":"Cristofano","year":"2016","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4149\/bll_2014_061","article-title":"Disorders associated with abnormal acylcarnitine profile among high risk Egyptian children","volume":"115","author":"El-Mesellamy","year":"2014","journal-title":"Bratisl. Lek\u00e1rske Listy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/pr.2014.142","article-title":"Analysis and interpretation of acylcarnitine profiles in dried blood spot and plasma of preterm and full-term newborns","volume":"77","author":"Gucciardi","year":"2015","journal-title":"Pediatr. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0736-4679(01)00360-2","article-title":"Cerebrospinal fluid","volume":"21","author":"Jerrard","year":"2001","journal-title":"J. Emerg. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.plipres.2009.08.004","article-title":"Acylcarnitines: role in brain","volume":"49","author":"Jones","year":"2010","journal-title":"Prog. Lipid Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9010937","DOI":"10.1155\/2020\/9010937","article-title":"Changes in amino acid and acylcarnitine plasma profiles for distinguishing patients with multiple sclerosis from healthy controls","volume":"2020","author":"Kasakin","year":"2020","journal-title":"Mult. Scler. Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/gm337","article-title":"Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update","volume":"4","author":"Mandal","year":"2012","journal-title":"Genome Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","article-title":"Tuberculous meningitis: a uniform case definition for use in clinical research","volume":"10","author":"Marais","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1403312","DOI":"10.3389\/fneur.2024.1403312","article-title":"LC\u2013MS metabolomics and lipidomics in cerebrospinal fluid from viral and bacterial CNS infections: a review","volume":"15","author":"Plaatjie","year":"2024","journal-title":"Front. Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"29366","DOI":"10.1038\/s41598-025-15000-0","article-title":"CSF carnitine is a potential biomarker in paediatric tuberculous meningitis","volume":"15","author":"Plaatjie","year":"2025","journal-title":"Sci. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.20883\/jms.2019.335","article-title":"LC-MS\/MS based targeted metabolomics method for analysis of serum and cerebrospinal fluid","volume":"88","author":"Plewa","year":"2019","journal-title":"J. Med. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1038\/s41598-017-06767-y","article-title":"Decreased long-chain acylcarnitines from insufficient \u03b2-oxidation as potential early diagnostic markers for Parkinson\u2019s disease","volume":"7","author":"Saiki","year":"2017","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1212\/wnl.50.6.1869","article-title":"CSF levels of carnitine in children with meningitis, neurologic disorders, acute gastroenteritis, and seizure","volume":"50","author":"Shinawi","year":"1998","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1103026","DOI":"10.3389\/fneur.2023.1103026","article-title":"Correlation between blood glucose and cerebrospinal fluid glucose levels in patients with differences in glucose metabolism","volume":"14","author":"Tan","year":"2023","journal-title":"Front. Neurology"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1643667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:16:51Z","timestamp":1759292211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1643667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":17,"alternative-id":["10.3389\/fmolb.2025.1643667"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1643667","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1643667"}}